NCT07143097View on ClinicalTrials.gov

Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 30, 2024

Study Completion Date

May 30, 2025

Conditions
Triple -Negative Breast Cancer
Interventions
DRUG

capecitabine

capecitabine 650 mg / m2 twice per day for one year

Trial Locations (1)

Unknown

Faculty of Medicine, Banī Suwayf

All Listed Sponsors
lead

Beni-Suef University

OTHER

NCT07143097 - Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer | Biotech Hunter | Biotech Hunter